The PD-1 and PD-L1 inhibitor market is witnessing robust growth driven by advances in immuno-oncology and rising adoption across multiple cancer therapies. Increasing clinical approvals and expanding indications continue to reshape the competitive landscape, presenting broad market growth strategies and opportunities globally https://hallbook.com.br/blogs/823937/PD-1-and-PD-L1-Inhibitor-Market-Growth-Fueled-by